Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme

Mycoplasma genitalium (Mgen) is classified as a sexually transmitted disease and is commonly treated with macrolide-based antibiotics. As rapid molecular tests for Mgen drug resistance have been developed, laboratories need appropriate external quality assessment (EQA) schemes to meet the quality control requirements. Labquality has introduced a new EQA scheme Mycoplasma genitalium, drug resistance, nucleic acid detection, to support the quality control of nucleic acid tests (NAT) incorporating detection of mutations associated with macrolide resistance for Mgen.